Transaction Overview - On December 26, 2023, the board of directors of Henan Tailong Pharmaceutical Co., Ltd. approved a proposal for joint acquisition of fund shares and change of fund manager, allowing its wholly-owned subsidiary, Hangzhou Tailong Jintang Enterprise Management Co., Ltd., to acquire 0.67% of the ordinary partnership shares of the Henan Jinggang Advanced Manufacturing Equity Investment Fund for RMB 2.1979 million [2] - The company’s wholly-owned subsidiary Zhengzhou Longhua Pharmaceutical Industry Fund Partnership will acquire 82.33% of the limited partnership shares of the Jinggang Fund for RMB 190.9653 million, resulting in a total holding of 55% partnership shares [2] - The fund manager will be changed to Tibet Jinyuan Investment Management Co., Ltd. [2] Transaction Progress - By August 2024, the transaction payment and share transfer will be completed, and a new partnership agreement will be signed with all partners, officially changing the fund manager to Tibet Jinyuan Investment Management Co., Ltd. [3] - The fund will complete its business registration and obtain a business license [3] - The fund management change has been registered with the Asset Management Association of China, confirming the new management structure [5] Fund Structure Changes - After the changes, the partnership structure of the Jinggang Fund will be updated, with the management company renamed to Jinyu Maowu (Tibet) Venture Capital Management Co., Ltd. [4] - This name change does not affect the rights and obligations under the partnership agreement [4]